Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Review
Nature Reviews Immunology 6, 343–357 (1 May 2006) | doi:10.1038/nri1837
Potent antibody therapeutics by design
Abstract
Antibodies constitute the most rapidly growing class of human therapeutics and the second largest class of drugs after vaccines. The generation of potent antibody therapeutics, which I review here, is an iterative design process that involves the generation and optimization of antibodies to improve their clinical potential.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
